These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31544267)

  • 21. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis.
    Zeng H; Luo M; Li Z; Wen J; He G; Jin Y; Fu W; Zhou P
    BMJ Open; 2019 Jul; 9(7):e029426. PubMed ID: 31352420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis.
    Yu AQ; Le J; Huang WT; Li B; Liang HX; Wang Q; Liu YT; Young CA; Zhang MY; Qin SL
    Adv Ther; 2021 Feb; 38(2):1275-1289. PubMed ID: 33421022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.
    Neff LM; Broder MS; Beenhouwer D; Chang E; Papoyan E; Wang ZW
    Clin Obes; 2017 Dec; 7(6):337-346. PubMed ID: 28891142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
    Chilton M; Dunkley A; Carter P; Davies MJ; Khunti K; Gray LJ
    Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG; Abel B; Zecca C; Saunders KH; Shukla AP
    Expert Opin Pharmacother; 2020 Jan; 21(1):21-28. PubMed ID: 31693425
    [No Abstract]   [Full Text] [Related]  

  • 33. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
    Tuccinardi D; Farr OM; Upadhyay J; Oussaada SM; Mathew H; Paschou SA; Perakakis N; Koniaris A; Kelesidis T; Mantzoros CS
    Diabetes Obes Metab; 2019 Jun; 21(6):1487-1492. PubMed ID: 30724455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
    Zhang R; Hou QC; Li BH; Deng L; Yang YM; Li TX; Yao XQ; Yang LL; Lin XL; Liao YQ; Wang L; Liu YP; Tan J; Wan ZW; Shuai P
    Front Endocrinol (Lausanne); 2023; 14():1132004. PubMed ID: 37455913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Hurren KM; Dunham MW
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
    Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
    Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Lifestyle Intervention on Cardiometabolic Risk Factors in Overweight and Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
    Khatlani K; Njike V; Costales VC
    Metab Syndr Relat Disord; 2019 Dec; 17(10):473-485. PubMed ID: 31513475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.